For example, in the production of active ingredients, Europe’s market share by value has slumped. While it exceeded 80% at the end of the 1990s, it had fallen to 48% by 2014. “Today, it’s closer to 30%, and it’s likely to drop further,” noted Vincent Touraille, president of SICOS, France’s union of players in the organic chemistry and biochemistry industries. Meanwhile, China and India have soared to reach respective market shares of 35% and 20%.
A study conducted by German generic drug industry association Pro Generika found that at least three commonly used antibiotics – doxycycline, clarithromycin and cefaclor – now have only one or two manufacturers left in Europe. More broadly, 80% of the active ingredients in medicines consumed on the continent now come from India or China.
This is a big subject in France right now (le monde is a French newspaper) because a very common French drug brand was recently sold to American investors: https://www.lemonde.fr/en/france/article/2024/10/14/sale-of-french-painkiller-to-american-firm-sparks-uproar_6729399_7.html
Yet the article above leads with a picture of a brand new Sanofi factory.
Not sure I want to contradict you; frankly the discrepancy between this article’s title and content confuses me.
I don’t have an opinion either way, I’m just relaying what’s in the media. I would say that a single factory doesn’t say much of anything about larger trends in the industry though.